EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR T cell therapies for diffuse midline glioma

Bryce C Thomas, Dilana E Staudt, Alicia M Douglas, Michelle Monje, Nicholas A Vitanza, Matthew D Dun

Trends in Cancer · 2023-10 · 9 (10) · 791-804

DOI: 10.1016/j.trecan.2023.07.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-10. Verfasst von Bryce C Thomas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine, and Wellbeing, University of Newcastle, Ca…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Glioma. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ChadTough Foundation, Jeffrey Thomas Hayden Foundation, Australian Lions Childhood Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse midline glioma (DMG) is a fatal pediatric cancer of the central nervous system (CNS). The location and infiltrative nature of DMG prevents surgical resection and the benefits of palliative radiotherapy are temporary; median overall survival (OS) is 9-11 months. The tumor immune microenvironment (TIME) is 'cold', and has a dominant immunosuppressive myeloid compartment with low levels of infiltrating lymphocytes and proinflammatory molecules. Because survival statistics have been stagnant for many decades, and therapies targeting the unique biology of DMG are urgently needed, this has prompted the clinical assessment of chimeric antigen receptor (CAR) T cell therapies in this setting. We highlight the current landscape of CAR T cell therapy for DMG, the role the TIME may play in the response, and strategies to overcome treatment obstacles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveGliomaChildHumansCentral Nervous SystemTumor Microenvironment

Stichwörter der Autor:innen

CNS tumorschimeric antigen receptor T cell therapydiffuse midline gliomalocoregional infusiontumor immune microenvironment

Autor:innen und Institutionen

  • Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine, and Wellbeing, University of Newcastle, Callaghan, NSW, Australia; Precision Medicine Research Program, Hunter M…
  • Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Department of Pediatrics, Stanford University, Stanford, CA, USA; Department of Neurology and Neurological Scie…
  • Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.

Förderung

  • ChadTough Foundation
  • Jeffrey Thomas Hayden Foundation
  • Australian Lions Childhood Cancer Research Foundation
  • Robert Connor Dawes Foundation
  • Musella Foundation For Brain Tumor Research and Information
  • Charlie Teo Foundation
  • Cure Starts Now Foundation
  • Hunter Medical Research Institute

Zitieren

APA

Thomas, B. C., Staudt, D. E., Douglas, A. M., Monje, M., Vitanza, N. A., & Dun, M. D. (2023). CAR T cell therapies for diffuse midline glioma. Trends in Cancer, 9(10), 791-804. https://doi.org/10.1016/j.trecan.2023.07.007

Vancouver

Thomas BC, Staudt DE, Douglas AM, Monje M, Vitanza NA, Dun MD. CAR T cell therapies for diffuse midline glioma. Trends in Cancer. 2023;9(10):791-804. doi:10.1016/j.trecan.2023.07.007

BibTeX
@article{Thomas2023,
  author = {Thomas, Bryce C and Staudt, Dilana E and Douglas, Alicia M and Monje, Michelle and Vitanza, Nicholas A and Dun, Matthew D},
  title = {CAR T cell therapies for diffuse midline glioma},
  journal = {Trends in Cancer},
  year = {2023},
  volume = {9},
  number = {10},
  pages = {791--804},
  doi = {10.1016/j.trecan.2023.07.007}
}
Kostenlos starten →